CLAIMS

WHAT IS CLAIMED IS:

1. A composition for use in the prevention or the treatment of macular degeneration, glaucoma, or diabetic retinopathy comprising active ingredients of :

(a) at least one bile acid selected from an ursodeoxycholic acid (UDCA), a tauroursodeoxycholic acid(tUDCA) and a glycoursodeoxycholic acid(gUDCA);

(b) an aqueous soluble starch conversion product; and

(c) water,

wherein the composition is a clear aqueous solution when the pH value of the composition is 6 – 9;

wherein the aqueous soluble starch conversion product is maltodextrin and the minimum weight ratio of the bile acid to the maltodextrin is 1:13; and

wherein a daily dose of the bile acid of the composition for an oral administration is 5 - 30 mg/kg and the bile acid is delivered in a therapeutically active amount to the eyeball across the blood-retinal barrier.

2. The composition of claim 1, wherein the composition is to be administered at least once a day for 20 days or more.

3. The composition of claim 1 or claim 2, wherein the macular degeneration is wet age-related macular degeneration.

4. The composition of claim 1 or claim 2, wherein the composition has at least one function of inhibiting the development of choroidal neovascularization, promoting the recovery of retinal function, and regulating the expression level of vascular endothelial growth factor (VEGF).

5. The composition of claim 1 or claim 2, wherein the bile acid is present in a therapeutically active amount.

6. The composition of claim 1 or claim 2, wherein the bile acid is included in an amount of 0.01 - 5 parts by weight based on the total weight of the composition.

7. The composition of claim 3, wherein the bile acid is included in an amount of 0.04 - 0.16 parts by weight based on the total weight of the composition.

8. The composition of claim 1 or claim 2, wherein the aqueous soluble starch conversion product is maltodextrin and the maltodextrin is contained in an amount of 1 - 70 parts by weight based on the total weight of the composition.

9. The composition of claim 1 or claim 2, wherein the pH value of the composition is 6.5 - 8, and the aqueous soluble starch conversion product is maltodextrin, and the minimum weight ratio of the ursodeoxycholic acid to the maltodextrin is 1:13 - 1:30.

10. The composition of claim 1 or claim 2, wherein the aqueous soluble starch conversion product further comprises at least one selected from dextrin, liquid glucose, corn syrup solid, soluble starch, dextran, guar gum, pectin and soluble non-starch polysaccharide.

11. The composition of claim 1 or claim 2, wherein the composition is to be administered together with a therapeutic agent for macular degeneration.

12. The composition of claim 11, wherein the therapeutic agent for macular degeneration is an anti-vascular endothelial growth factor antibody.

13. The composition of claim 12, wherein the therapeutic agent for macular degeneration is prepared for an intravitreal injection.